Phynova completes enrollment in PYN17 trial

Phynova, a developer of prescription pharmaceuticals derived from Chinese botanical medicines, has completed patient enrollment for its ongoing Phase I/II clinical trial of PYN17, which is being conducted in five hepatology centers in the USA.

The agent is the only product currently in clinical development that is specifically aimed at treating the debilitating symptoms and impaired health-related quality of life and liver inflammation in chronic hepatitis C. The double-blind trial, which commenced on May 29, has enrolled 39 patients as planned, randomized to treatment with either PYN17 or placebo and no serious adverse events have been reported to date.

Robert Miller, Phynova's chief executive, said "dosing in this study should be completed by mid-September, with interim clinical results available later this quarter. We look forward to working with the US Food and Drug Administration at that time, as planned, to work towards commencing a Phase IIb study early in 2008."